News archives

Home > News archives

Closing of the funding to boost R&D

Aug 28,2018 -- Updated 18:53 +0900 (GMT)

Sapporo, Japan, May 31, 2018 – NB Health Laboratory Co. Ltd. (Head Office: Kita-Ku, Sapporo; President: Kiyoshi Takayama, Ph.D.) today announced that NBHL has raised ¥360 million in an equity funding round through Fast Track Initiative Fund II, L.P., ANNIVERSAIRE HOLDINGS INC., SMBC Venture Capital Fund IV, L.P. and Hokkaido Seichou Kigyou Fund, L.P. The funds will be used to boost the development of NBHL GPCR mAb technology (MoGRAA® discovery engine) and strengthen the corporate system.

NBHL’s article “MoGRAA® discovery engine” published in journal of PSJ

Mar 9,2018 -- Updated 10:31 +0900 (GMT)

NBHL’s article “MoGRAA® discovery engine for the discovery of functional mAb therapeutics targeting GPCRs” has been published in Farumashia, the journal of The Pharmaceutical Society of Japan.
Farumashia Vol.54 No.3: 246-248 (2018) [in Japanese]

Closing of the funding to accelerate R&D

Nov 2,2016 -- Updated 22:48 +0900 (GMT)

Sapporo, Japan, Oct. 28, 2016 – NB Health Laboratory Co. Ltd. (Head Office: Kita-Ku, Sapporo; President: Kiyoshi Takayama, Ph.D.) today announced that NBHL has raised ¥200 million in an equity funding round through Fast Track Initiative Fund II, L.P.
managed by Fast Track Initiative, Inc. (Head Office: Bunkyo-Ku Tokyo; CEO Hiromichi Kimura, PhD). The funds will be used to accelerate development of NBHL original bio medicine.

NBHL will participate in “BioJapan 2016” in Yokohama.

Sep 21,2016 -- Updated 17:32 +0900 (GMT)

NBHL will hold a panel exhibition at A-35 (in Hokkaido Bio Cluster booth)  in “BioJapan 2016”, held from October 12th to 14th, 2016 in Pacifico Yokohama, Japan. We will present “MoGRAA™ discovery engine”, our technology platform for GPCR antibody production.

Announcement of Agreements with Shionogi & Co., Ltd. for Research Collaboration and Grant of First Refusal Right

Jul 15,2016 -- Updated 15:00 +0900 (GMT)

Press Relese_2016.7.15 

NBHL’s headquarters and the laboratory have moved.

Jun 22,2016 -- Updated 12:00 +0900 (GMT)

Due to the business expansion, NBHL’s headquarters and Sapporo laboratory moved to the new address below on the 22nd of June.

Headquarters
#301, North 21 West 12-2, Kita-Ku, Sapporo,
Hokkaido 001-0021, Japan

The president of NBHL will present as a guest speaker in “Discovery On Target 2016” in Boston.

May 23,2016 -- Updated 09:01 +0900 (GMT)

NBHL will participate in the upcoming “Discovery On Target 2016”, held in Boston from September 20th to 22nd, 2016. The president of NBHL will present its proprietary technology “MoGRAA discovery engine” as a guest speaker at the Conference: Antibodies Against Membrane Protein Targets– Part 1 on September 20th.

[“Discovery On Target 2016” website:URL→ http://www.discoveryontarget.com/ ]

NBHL will participate in “2016 BIO International Convention” in San Francisco.

May 23,2016 -- Updated 09:00 +0900 (GMT)

NBHL will hold a booth at the Japan pavilion in “2016 BIO International Convention”, held from June 6th to 9th, 2016 in San Francisco.

[“2016 BIO International Convention” website: URL→http://convention.bio.org/2016/]

We have revamped the website in Japanese.

May 10,2016 -- Updated 11:15 +0900 (GMT)

We have revamped the website in Japanese.
日本語版HPをリニューアルしました。
http://www.nbhl.co.jp/jp/

NBHL will present our functional antibodies against GPCR, at International Symposium for Medicinal Sciences.

Mar 8,2016 -- Updated 10:00 +0900 (GMT)

The head of laboratory of NBHL will present our technology platform of functional antibodies against GPCR at International Symposium for Medicinal Sciences held on March 28th, 2016, during the 136th annual meeting of the Pharmaceutical Society of Japan in Yokohama.

次へ »